Terbinafine

Chemical formula: C₂₁H₂₅N  Molecular mass: 291.43 g/mol  PubChem compound: 1549008

Therapeutic indications

Terbinafine is indicated for:

Tinea corporis, tinea cruris, tinea pedis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Treatment of fungal infections of the skin and nails, which is caused by Trichophyton (e.g. T. rubrum, T.mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Onychomycosis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

The treatment of onychomycosis caused by dermatophytes (Trichophyton e.g. T. rubrum, T.mentagrophytes, T. verrucosum, T. violaceum, Microsporum canis and Epidermophyton floccosum.).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Cutaneous candida

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Candidiasis of skin

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pityriasis versicolor

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Pityriasis versicolor

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Terbinafine is contraindicated in the following cases:

Hypersensitivity to terbinafine

at least one of
Terbinafine allergy
Terbinafine adverse reaction

Severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Severe hepatic impairment

Hepatic failure stage IV

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: TERBINAFINE MYLAN Cream
Summary of Product Characteristics (SPC) 2018: TERBINAFINE ACCORD Tablet
Summary of Product Characteristics (SPC) 2017: LAMISIL Tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈